Report date: Dec 2,2025
Conflict count: 369596
Publisher: Sunvalley Communication
Title count: 1
Conflict count: 1


==========================================================

Created: 2025-09-23 04:46:26
ConfID: 8314736
CauseID: 1713376196
OtherID: 1713375868
JT: ADC Review / Journal of Antibody-drug Conjugates
MD: Hofland,,,,2025,NICE Approves Enfortumab Vedotin + Pembrolizumab as First-line Treatment for Adults with Metastatic Urothelial Cancer in the UK
DOI: 10.14229/jadc.2025.09.12.001(Journal) (8314736-N)
DOI: 10.14229/jadc.2025.09.12.002(Journal)